Citations

Clear

350 citation(s) found for "Stevens, V".

Anticalcitonin: limited utility of a context-dependent biomarker demonstrated in another real-world data set
Ilges, Dan , Shah, Aditya , Stevens, Ryan W. , McCreary, Erin K, Stevens, Ryan W , Ilges, Dan , McCreary, Erin K

Mayo Clinic

Clinical Infectious Diseases | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag396 | PMID 42386194 Get It

Metastatic pleural mesothelioma presenting as ulcerated submucosal colonic nodules
Kiliaki, Shangwe A. , Stevens, Kent, Kiliaki, Shangwe

Mayo Clinic

Journal of the American Association of Nurse Practitioners | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/jxx.0000000000001291 | PMID 42360025 Get It

ABSTRACT Malignant pleural mesothelioma is a rare and aggressive malignancy associated with poor prognosis. Although it typically spreads through local invasion, distant metastasis to the gastrointestinal tract is uncommon, and colonic involvement is particularly rare. We report a case of metastatic pleural mesothelioma presenting as ulcerated submucosal nodules in the colon. The patient had previously elected active surveillance for known malignant pleural mesothelioma because of poor performance status and multiple medical comorbidities. Approximately 18 months after diagnosis, he was hospitalized with rectal bleeding and diarrhea. Colonoscopy revealed ulcerated submucosal nodules within the colon, and histopathologic evaluation of biopsy specimens demonstrated colonic mucosa infiltrated by malignant mesothelioma. Systemic therapy was not recommended for bleeding control given the patient's overall clinical condition. Management consisted of supportive care, including one packed red blood cell transfusion and serial hemoglobin monitoring. While prior reports describe colonic metastases presenting as polyps or intussusception, this case highlights an atypical manifestation of mesothelioma involving ulcerated submucosal colonic nodules. Recognition of this rare presentation may aid clinicians evaluating gastrointestinal bleeding in patients with mesothelioma.
Ambulatory antibiotic prescribing for acute sinusitis: a multicenter, retrospective cohort study evaluating appropriateness
Hannan, Kellie N. Arensman , Ilges, Dan , Le, Kimberly T. , Mara, Kristin C. , Stevens, Ryan W., Jensen, Kelsey , Arensman Hannan, Kellie , Mara, Kristin C , Jensen, Kelsey , Ilges, Dan , Le, Kimberly Thi , Stevens, Ryan W.

Mayo Clinic

Antimicrobial Stewardship & Healthcare Epidemiology | June 25, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1017/ash.2026.10743 | PMID 42375666 Get It

Abstract Objective: Antibiotics are frequently prescribed for acute sinusitis despite national guidelines recommending antibiotics only if specific symptom criteria are met. We aimed to define the proportion of acute sinusitis encounters meeting criteria for antibiotic prescribing, characterize prescribing practices, and identify factors associated with guideline-discordant prescribing. Design: This retrospective cohort study included 1,000 randomly selected adult ambulatory encounters with a primary diagnosis of acute sinusitis between January 1, 2024 and March 31, 2024. Encounter notes were reviewed for appropriate antibiotic prescribing criteria as per national guidelines. Encounters were evaluated for drug selection and duration concordance based on local guidelines. A multivariable logistic regression analysis was performed to identify predictors of inappropriate antibiotic prescribing. Setting: Emergency departments, urgent care centers, and primary care clinics. Results: Antibiotic prescribing criteria were met for 67.6% of included encounters. Antibiotics were prescribed in 93.5% of encounters that met prescribing criteria, and 80.2% of encounters that did not. Both drug selection and duration were guideline-concordant in 49.2% of total encounters. On multivariable analysis, predictors of inappropriate antibiotic prescribing included cough (OR 2.15, 95% CI 1.08–4.29; P = 0.03) and symptom duration between 7 and 9 days (compared to <6 days; OR 7.70, 95% CI 3.24–18.31; P < 0.001). Electronic encounters were associated with lower odds of prescribing compared to in-person encounters (OR 0.03, 95% CI 0.01–0.09; P < 0.001). Conclusions: Most encounters for acute sinusitis result in an antibiotic prescription, despite prescribing criteria not being met. These findings may aid antimicrobial stewardship programs in benchmarking and optimizing antibiotic prescribing for acute sinusitis.
Designing Artificial Intelligence Tools to Strengthen Human Connection in Healthcare: The CoCo Experience
Eliáš, Richard , Grimsley, Shawn M., Werneburg, Brooke L., Stevens, Sheila K., Kane, Sunanda, Elias, Richard M

Mayo Clinic

Journal of Patient Experience | June 18, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/23743735261461903 | PMID 42344231 Get It

Healthcare organizations face persistent tension between efficiency and human connection. Digital systems often fragment attention and unintentionally distance staff from patients. At Mayo Clinic, we developed a conversational artificial intelligence (AI) agent embedded in Microsoft Teams to address this challenge. Connecting and Communicating (CoCo) provides staff with communication guidance, drawing on institutional resources aligned with the Mayo Model of Communication (MMOC). Built in Microsoft Copilot Studio and shaped by clinicians and operational stakeholders, CoCo was designed to be values-aligned and usable within existing workflows. CoCo is an active, user-initiated tool used primarily before or after challenging interactions to support preparation, reflection, and communication planning. Staff valued CoCo as a “just-in-time coach” that reinforced empathy while reducing stress. From August 2025 through February 2026, CoCo supported 1,903 conversation sessions, with early descriptive analytics suggesting favorable satisfaction and response-quality signals. We share insights from development and deployment, along with practical recommendations, to support other organizations considering bespoke, values-aligned AI tools to enhance patient and staff experience. We distill practice-based implementation lessons around governance, human factors, and change management, and offer practical recommendations to inform similar efforts elsewhere.
Crushed posaconazole delayed-release tablets via enteric feeding tube administration: practical considerations for clinicians
Bhattarai, Nirjan , Ilges, Dan , Stevens, Ryan W. , Stevens, Ryan W , Ilges, Dan

Mayo Clinic

Journal of Antimicrobial Chemotherapy | May 28, 2026 | Volume: 81 | Issue: 7 | Pages: No page available

10.1093/jac/dkag201 | PMID 42258600 Get It

Abstract Posaconazole delayed-release (DR) tablets are labelled as ‘do not crush’ medications. Despite this designation, emerging research demonstrates successful attainment of therapeutic serum concentrations, suggesting that they may be pharmacokinetically superior to the immediate-release (IR) suspension when given via enteric feeding tube (EFT). While crushed posaconazole DR tablets may be better suited than the IR suspension to attain therapeutic serum concentrations, several practical factors must be considered, including lack of dose equivalency between crushed DR tablets for EFT administration and DR tablets swallowed whole and the risk of EFT occlusion. This article summarizes the current evidence on posaconazole serum concentrations with crushed DR tablets administered via EFT, explores risks of this practice and provides mitigation strategies for application in the clinical setting, including proposed dosing and administration practices.
Final results of a single-arm, open-label, multicenter phase 2 study of the radiopharmaceutical [ 177 Lu]Lu-DOTA-TATE and [ 68 Ga]Ga-DOTA-TATE in adults w
Kurz, Sylvia C. , Zan, Elçin , Peereboom, David M., Malkin, Mark G. , Miller, Alexandra , Dhawan, Andrew, Torres-Trejo, Alejandro, Stevens, Glen , Snuderl, Matija, Zagzag, David , Golfinos, John G. , Kondziolka, Douglas, Troxel, Andrea, Friedman, Kent P., Shepherd, Timothy, Peereboom, David M. , Cordova, Christine , Sulman, Erik P. , Lobbous, Mina , Barbaro, Marissa , Dhawan, Andrew , Silverman, Joshua S. , Snuderl, Matija , Kondziolka, Douglas, Troxel, Andrea B. , Friedman, Kent, Shepherd, Timothy M.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 2090-2090

10.1200/jco.2026.44.16_suppl.2090 Get It

2090 Background: A subset of meningiomas has an aggressive clinical course requiring multimodal therapies. Yet, treatment options beyond surgery and radiation are limited. Somatostatin receptor 2 (SSTR2) is uniformly expressed in meningiomas and can be targeted by the radiopharmaceutical agent [ 177 Lu]Lu-DOTA-TATE ( 177 Lu-Dotatate). [ 68 Ga]Ga-DOTA-TATE ( 68 Ga-Dotatate) PET is emerging as a promising imaging modality to assess treatment response in SSTR2-expressing tumors. However, prospective clinical data supporting the use of 177 Lu-Dotatate and 68 Ga-Dotatate in treatment-refractory meningiomas is limited. Methods: In this multicenter, open-label, phase 2 clinical study (NCT03971461), adult patients with progressive intracranial meningiomas received 177 Lu-Dotatate at 7.4 GBq (200 mCi) every 8 weeks for 4 doses. The primary endpoint was 6-month progression-free survival (PFS-6). Up to 5 meningioma lesions per patient were assessed by gadolinium-enhanced T1 MRI every 12 weeks. 68 Ga-Dotatate PET was obtained before/after 177 Lu-Dotatate treatments. Lesional 68 Ga-Dotatate PET activity was assessed relative to liver/spleen or superior sagittal sinus (SSS). Results: 32 patients (female = 21, male = 11) with progressive meningiomas (WHO grade 1 = 7, grade 2 = 24, grade 3 = 1) were enrolled. Median age was 65.5 (range 41-78) years. All patients had at least one prior tumor surgery and at least one course of radiation. Overall, 177 Lu-Dotatate was well tolerated and the most common grade 3/4 adverse events were transient cytopenia in 15 patients (47%). One patient (3%) discontinued treatment due to grade 4 thrombocytopenia. PFS-6 was reached in 22 patients (69%), which includes 5 of 7 (71%) with grade 1 and 17 of 24 (71%) with grade 2 meningiomas. Best radiographic response by MRI was partial response (PR) in 5 (16%) and stable disease (SD) in 20 (63%) patients. Eight patients (16 lesions) were evaluable by paired MRI and 68 Ga-Dotatate PET pre- and post-treatment. Referenced to SSS, 68 Ga-Dotatate avidity reduced by ≥50% in 2 lesions (PR), 25-49% (minor response, MR) in 3 lesions and remained stable ( < 25% reduction and < 25% increase) in 11 lesions. Using liver/spleen as a reference (6 patients, 14 lesions), 68 Ga-Dotatate uptake was reduced in 9 lesions and stable in 5 lesions. 68 Ga-Dotatate PET assessments were generally concordant with MRI-based treatment response assessments. Conclusions: The primary endpoint (PFS-6) was met in this phase 2 study with 69% of patients achieving PFS-6, thereby surpassing established historical benchmarks. 177 Lu-Dotatate was generally well tolerated and deserves further study in patients with advanced meningiomas. Exploratory 68 Ga-DOTATATE PET studies showed decreased uptake in a subset of lesions and bears promise as an imaging biomarker to assess treatment response. Clinical trial information: NCT03971461 .
Early Experience With Beta-Lactam Therapeutic Drug Monitoring in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program
Barrett, Kemar O. , Rivera, Christina G. , Saleh, O. Abu, Pertzborn, Margaret , Ausman, Sara , Hannan, Kellie Arensman, Stevens, Ryan W. , Barreto, E, Hannan, Kellie N. Arensman , Abu Saleh, Omar , Ausman, Sara E , Arensman Hannan, Kellie , Stevens, Ryan W , Rivera, Christina G , Barrett, Kemar O , AbuSaleh, Omar, Rule, Andrew D. , Frazee, Erin N.

Mayo Clinic

Open Forum Infectious Diseases | May 22, 2026 | Volume: 13 | Issue: 5 | Pages: No page available

10.1093/ofid/ofag299 | PMID 42221364 Get It

Abstract We describe early experience with beta-lactam therapeutic drug monitoring (TDM) in a high-volume outpatient parenteral antimicrobial therapy program. In selected patients, TDM informed dose optimization and toxicity mitigation. Illustrative cases highlight feasibility and emerging lessons supporting beta-lactam TDM in outpatient care.
Resolving inflammatory bowel disease risk variants to genes and cell types
Zhang, Rui, Gettler, Kyle , Haritunians, Talin , Cleynen, Isabelle , Stevens, Christine R , Zhang, Qian , Tastad, Christopher, Medici, Catalina, Abreu, María T. , Achkar, Jean-Paul, Ahmad, Tariq, Bernstein, Charles, Brooks, Johanne , Bujanda, Luis, Butterworth, Jeffrey, Clark, Katie, Cummings, F, Buono, Joanne Del, Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Jarvis, Mark , Johnston, EL, Kemp, Cheryl, Kennedy, Nick, Lewis, James D. , Li, Andy, Louis, Édouard , Moayyedi, Paul, Moran, G , Newman, Bill, Oglesby, Arabis, Pekow, Joel, Perez, Kate J., Pollok, R, Radford-Smith, Graham , Raffals, L, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Reinisch, Walter , Satsangi, Jack, Selinger, Christian, Shedwell, Sophy, Silverberg, Mark S. , Singh, Salil, Steel, Alan, Uhlig, Holm H. , Verma, Ajay, Weersma, Rinse K. , Xavier, Ramnik, Parkes, M, Lee, James C. , McGovern, D, Anderson, Carl A. , Lee, James , Raine, Tim , Zhang, Rui , Haritunians, Talin , Raine, Tim , Anderson, Carl A , Fachal, Laura , Cleynen, Isabelle , Stevens, Christine R. , Zhang, Qian , Tastad, Christopher , Do, Ron , Achkar, Jean–Paul , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , D’Amato, Mauro , Duerr, Richard H , Ellinghaus, David , Franchimont, Denis , Franke, André , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Julià, Antonio , Kennedy, Nicholas Alexander , Kupcinskas, Juozas , Latiano, Anna , Lewis, James D , McLaughlin, John , Moayyedi, Paul , Mowat, Craig , Newberry, Rodney D. , Perez, Kate J, Prescott, Natalie , Radford‐Smith, Graham L , Raffals, Laura E. , Reinisch, Walter , Rogler, Gerhard , Sands, Bruce E , Satsangi, Jack, Scharl, Michael , Schreiber, Stefan , Sebastian, Shaji , Selinger, Christian P. , Steed, Helen , Vermeire, Séverine , Halfvarson, Jonas , Daly, Mark J. , Lamb, Christopher A , Huang, Hailiang , McGovern, Dermot P.B. , Rioux, John D. , Cho, Judy H , Zhang, Rui

Mayo Clinic

No container title available | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.13.26352926 Get It

Abstract Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
C39-12 Risk of Progressive Pulmonary Fibrosis Among Patients With Systemic Autoimmune Rheumatic Diseases in a Multi-center Real-world Cohort
Durheim, M, Stevens, S, Aronson, K I, Burg, C A, Hewlett, J C, Horowitz, J C, Kennedy, C C, Lipchik, R J, Scholand, M, Soskis, A, Wruck, L, Palmer, S M, Swaminathan, A C, Wruck, Lisa , Wruck, Lisa M , Aronson, Kerri I. , Hewlett, Justin C. , Lipchik, Randolph J. , Scholand, M, Soskis, Alyssa , Swaminathan, A C

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2661 Get It

Abstract Rationale Patients with interstitial lung disease related to systemic autoimmune rheumatic diseases (SARD-ILD) may develop progressive pulmonary fibrosis (PPF), characterized by irreversible loss of lung function and high mortality risk. The risk of PPF by SARD subtype is not well characterized in large, representative real-world data sources. We characterized patients with SARD-ILD and compared the risk of PPF by SARD subtype in a multicenter cohort derived from the national Patient-Centered Clinical Research Network (PCORnet). Methods Harmonized electronic health record (EHR) data was collected from seven PCORnet centers. Included patients had at least two ICD-9/ICD-10 codes for ILD between 2015-2021, an ILD diagnosis that persisted following chest CT and/or lung biopsy, at least one year of potential follow-up, and sufficient lung function data to assess PPF. The presence of SARD, subtypes of which were classified by ICD codes, was also required. PPF was defined by ≥ 5% absolute decline in FVC, lung transplantation or death. The incidence of PPF was compared across SARD subtypes using Kaplan Meier estimates and Cox proportional hazards models adjusted for age, sex, enrolling center and baseline FVC. Results The cohort included 6,288 patients with SARD-ILD, of whom 68.4% were female, with a mean (SD) age of 61.2 (13.9) years. The most common underlying SARD was rheumatoid arthritis (RA, 42.8%), followed by systemic sclerosis (SSc, 22.3%), mixed connective tissue disease (MCTD, 21.5%), Sjögren’s syndrome (16.9%), systemic lupus erythematosus (SLE, 14.5%) and polymyositis/dermatomyositis (PM/DM, 12.0%). Mean FVC and DLCO at baseline were 78.7 (22.9) % and 51.9 (21.3) % of predicted, respectively. Patients with PM/DM had the lowest mean FVC (70.4 [SD 21.3]) % of predicted) and DLCO (45.1 [SD 18.5] % of predicted). During the follow-up period, antifibrotic, corticosteroid, and non-steroidal immunosuppressive drugs were used by 7.6%, 89.3% and 77.5% of the overall cohort, respectively. The cumulative incidence of PPF, transplant or death at one year ranged from 20.6% to 29.0%, depending on SARD-ILD subtype, with higher risk among those with RA, SSc or MCTD as compared with PM/DM (figure). Conclusions In a large, harmonized EHR dataset, the risk of PPF at one year among patients with SARD-ILD was high. Variability of PPF risk by SARD-ILD subtype was similar to that observed in traditional cohort studies, with lower risk among patients with myositis despite poorer lung function at baseline. These findings establish the feasibility of PCORnet as a tool to understand PPF among patients with SARD-ILD. This abstract is funded by: Genentech